News

Kaye Scholer Represents Novartis in Admune Acquisition

October 27, 2015

Kaye Scholer Represents Novartis in Admune Acquisition

Kaye Scholer advised longtime client Novartis in its acquisition of Admune Therapeutics, a Massachusetts-based clinical stage biotechnology company. The deal, announced October 21, broadens Novartis’ immuno-oncology pipeline. Terms of the deal were not disclosed.

With products available in more than 180 countries around the world, Basel, Switzerland-headquartered Novartis is the only global company with leading positions in innovative medicines, eye care and cost-saving generic pharmaceuticals.

The Kaye Scholer team for this transaction included Corporate partner Thomas Yadlon, counsel Aaron Gardner and associates Eric Levine, Christopher Konieczny and Michelle Han; Tax partner Laurie Abramowitz and associate Sarah Soloveichik; and Executive Compensation partner Jeff London and associate Brian Witkowski.

» Read the Novartis press release.

Email Disclaimer